1)Ljungberg B, Cowan NC, Hanbury DC, et al:EAU Guidelines on Renal Cell Carcinoma:The 2010 Update. EurUrol 58:398-406, 2010
2)http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
3)Motzer RJ, Bacik J, Murphy BA, et al:Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002
4)Naito S, Yamamoto N, Takayama T, et al:Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokines era:a cooperative group report of 1463 patients. Eur Urol 57:317-325, 2010
5)Escudier B, Eisen T, Stadler WM, et al:Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
6)Ueda T, Imamura Y, Komaru A, et al:Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. Int J Urol 17:811-815, 2010
7)Motzer RJ, Hutson TE, Tomczak P, et al:Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
8)Suyama T, Ueda T, Fukasawa S, et al:Efficacy and Safety of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma. J Caner Therapy 2:335-341, 2011
9)Motzer RJ, Escudier B, Oudard S, et al:Efficacy of everolimus in advanced renal cell carcinoma:a double-blind, randomised, placebocontrolled phase Ⅲ trial. Lancet 372:449-456, 2008
10)Hudes G, Carducci M, Tomczak P, et al:Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007
11)Areses MC, Herranz UA, Ferra'n BB, et al:Temsirolimus in renal cell carcinoma with sarcomatoid differentiation:a report of three cases. Med Oncol 2011, DOI 10.1007/s12032-011-9976-y
12)Haas NB, Lin X, Manola J, et al:A phase Ⅱ trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features:ECOG 8802. Med Oncol 2011, DOI:10.1007/s12032-011-9829-8.
13)White DA, Camus P, Endo M, et al:Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396-403, 2010
14)日本呼吸器学会薬剤性肺障害ガイドライン作成委員会編集:薬剤性肺障害の評価,治療についてのガイドライン.メジカルレビュー社,東京,2006
15)Kohno N:Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 46:151-158, 1999
16)Hartl D and Griese M:Surfactant protein D in human lung diseases. Eur J Clin Invest 36:423-435, 2006
17)Maertens J, Meersseman W and Van Bleyenbergh P:New therapies for fungal pneumonia. Curr Opin Infect Dis 22:183-190, 2009
18)Rini BI:Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 14:1286-1290, 2008
19)Hudes GR:Targeting mTOR in renal cell carcinoma. Cancer 115(10 suppl):2313-2320, 2009
20)Simpson D, et al:Temsirolimus in advanced renal cell carcinoma. Drugs 68:631-638, 2008